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Implications of scaling up cardiovascular disease treatment 
in South Africa: a microsimulation and cost-effectiveness 
analysis
Sanjay Basu, Ryan G Wagner, Ronel Sewpaul, Priscilla Reddy, Justine Davies
Summary
Background Cardiovascular diseases and their risk factors—particularly hypertension, dyslipidaemia, and diabetes—
have become an increasing concern for middle-income countries. Using newly available, nationally representative 
data, we assessed how cardiovascular risk factors are distributed across subpopulations within South Africa and 
identified which cardiovascular treatments should be prioritised.
Methods We created a demographically representative simulated population for South Africa and used data from 
17 743 respondents aged 15 years or older of the 2012 South African National Health and Nutrition Examination 
Survey (SANHANES) to assign information on cardiovascular risk factors to each member of the simulated 
population. We created a microsimulation model to estimate the health and economic implications of two globally 
recognised treatment recommendations: WHO’s package of essential non-communicable disease interventions 
(PEN) and South Africa’s Primary Care 101 (SA PC 101) guidelines. The primary outcome was total disability-
adjusted life-years (DALYs) averted through treatment of all cardiovascular disease or microvascular type 2 diabetes 
complications per 1000 population. We compared outcomes at the aspirational level of achieving access to 
treatment among 70% of the population.
Findings Based on the SANHANES data, South Africans had a high prevalence of hypertension (24·8%), 
dyslipidaemia (17·5%), and diabetes (15·3%). Prevalence was disproportionately high and treatment low among 
male, black, and poor populations. Our simulated population experienced a burden of 40·0 DALYs (95% CI 29·5–52·0) 
per 1000 population per year from cardiovascular disease or type 2 diabetes complications at current treatment levels, 
which lowered to 32·9 DALYs (24·4–44·7) under WHO PEN implementation and to 32·5 (24·4–44·8) under SA PC 
101 implementation. Under both guidelines, there were increases in blood pressure treatment (4·2 percentage points 
under WHO PEN vs 12·6 percentage points under SA PC 101), lipid treatment (16·0 vs 14·9), and glucose control 
medications (1·2 vs 0·6). The incremental cost-effectiveness of implementing SA PC 101 over current treatment 
would be a saving of US$24 902 (95% CI 14 666–62 579) per DALY averted compared with a saving of $17 587 
(1840–42 589) under WHO PEN guidelines.
Interpretation Cardiovascular risk factors are common and disproportionate among disadvantaged populations in 
South Africa. Treatment with blood pressure agents and statins might need greater prioritisation than blood glucose 
therapies, which contrasts with observed treatment levels despite a lower monthly cost of blood pressure or statin 
treatment than of sulfonylurea or insulin treatment.
Funding Stanford University.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Cardiovascular diseases and their risk factors—particularly 
hypertension, dyslipidaemia, and diabetes—have become 
an increasing concern in middle-income countries.1 Overall 
prevalence and mortality statistics for cardio vascular 
disease have been estimated since 1990 through imputation 
methods, providing a broad sense of the rising burden 
of disease at the country level1 and the expected economic 
consequences of non-communicable diseases,2 but 
detailed, nationally representative surveys of cardiovascular 
disease risk factors have only recently been completed. 
These surveys provide data to answer crucial questions 
such as the extent to which lower-income populations are 
affected compared with higher-income populations who 
might be less in need of public health sector interventions; 
which strategies and interventions (eg, blood pressure, 
lipid, or diabetes glucose manage ment) are highest 
priorities given the distribution of disease and avertable 
complications; and what level of health-care system 
budgeting might be necessary and cost-effective to scale up 
management. Despite these questions being posed,3–5 few 
studies have aimed to assess the implications of 
interventions for countries using real-population survey 
data rather than imputed aggregate country-wide averages.
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Questions about management of non-communicable 
diseases are of particular interest to policy makers in South 
Africa, a country with severe levels of poverty and inequality 
as a result of its apartheid history.6 South Africa notably 
continues to experience a high burden of HIV and 
tuberculosis, such that dual epidemics of infectious 
diseases and cardiovascular diseases co-occur in the 
population,7 with dire implications on limited health-care 
resources. Population-level chronic disease surveys done 
in South Africa since 2012 provide a uniquely compre-
hensive under standing of the variations in cardiovascular 
disease risk and availability and coverage of important 
cardio vascular disease risk factor management inter-
ventions.8 South Africa is also representative of many 
middle-income countries experiencing very large 
socioeconomic in equalities, a rapidly increasing burden of 
cardiovascular diseases and risk factors, and with a goal of 
providing more comprehensive health-care services by 
governments faced with a finite health-care budget.
Here, we address how cardiovascular risk factors are 
distributed across lower-income versus higher-income 
populations in South Africa, and which cardiovascular 
treatments should be prioritised. We capture both 
inequalities in risk factors and treatment access, in-
cluding for hypertension, dyslipidaemia, and type 2 
diabetes. We examine variations in cardiovascular disease 
risk factors by urban or rural residence, race and 
ethnicity, and socioeconomic status. We specifically 
integrate and use microsimulation to estimate the health 
and economic implications of scaling up treatment to 
meet recommendations in two alternative guidelines: 
WHO’s package of essential non-communicable disease 
interventions (PEN)9 and South Africa’s Primary Care 101 
(SA PC 101) guidelines.10 We additionally investigate 
whether implementation of either guideline would lead 
to a reduction in premature mortality (ie, <70 years of 
age) due to cardiovascular disease risk factors of 30% by 
2030, which is a key aim of the Sustainable Development 
Goals (target 3.4).3,4
Methods
Model overview
Modelling proceeded in three main steps (figure 1). First, 
a demographically representative simulated popu lation 
for South Africa was constructed using the 
most recent census data (ie, from 2011) and population 
projections from Statistics South Africa, incorporating 
estimated population sizes by age, sex, race and ethnicity, 
and socioeconomic status (as measured by the 
multidimensional poverty index).11,12
Second, we simulated the cardiovascular risk factors 
for each person in our population by repeated sampling 
from data from the 2012 South African National Health 
and Nutrition Examination Survey (SANHANES).8 
SANHANES was a stratified community-based survey, 
physical examination, and laboratory study of South 
Africans across urban and rural areas of all provinces, 
and had the most comprehensive data available to us 
Research in context
Evidence before this study
We searched PubMed on July 10, 2018, for the search terms 
“cardiovascular disease”, “blood pressure”, “lipid”, “diabetes” AND 
“low-income”, “middle income”, or “low- and middle-income”. 
Articles were restricted to English language original research 
papers published since 2000. Cardiovascular disease is becoming 
more prevalent in middle-income countries. Prior studies have 
identified key unanswered questions for public health and clinical 
practice: the extent to which lower-income populations in 
middle-income countries are affected compared with 
higher-income populations who might be less in need of public 
health sector interventions; which strategies and interventions 
(eg, blood pressure treatment, lipid treatment, or diabetes 
glucose management) are the highest priorities given the 
distribution of disease and avertable complications; and what 
level of health-care system budgeting might be necessary and 
the most cost-effective for scaling up of treatment. Few studies 
have aimed to assess the implications of interventions for 
countries using real-population survey data rather than imputed 
aggregate country-wide averages.
Added value of this study
We used nationally representative survey data from South Africa 
and a microsimulation model to estimate rates of cardiovascular 
and diabetes-related microvascular disease across demographic 
groups and to explore how implementation of available 
guidelines for cardiovascular risk factor control would affect the 
burden of cardiovascular disease and associated costs in the 
South African population. We found that high blood pressure, 
dyslipidaemia, and diabetes were prevalent across demographic 
groups, with low treatment levels (particularly for lipid 
treatment) among male, black African, and poor populations. 
Microsimulation results suggested that treatment with blood 
pressure agents and statins would need greater prioritisation 
than blood glucose medications; survey data, however, 
suggested that aggressive glucose control was more prevalent 
than guideline-based statin treatment, despite costs being 
lower for statins than for many common glucose agents.
Implications of all the available evidence
Assertive treatment of prevalent hypertension and 
dyslipidaemia might help to mitigate a high burden of disease 
in South Africa, including among historically disadvantaged 
populations. Implementation of available guidelines for 
cardiovascular risk factor control such as the WHO package of 
essential non-communicable disease interventions or the South 
African Primary Care 101 guidelines would be anticipated to 
enable achievement of Sustainable Development Goal 
target 3.4: reduction in premature mortality of 30%. 
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on measured cardiovascular disease risk factors. We 
sampled from the 17 743 individuals aged 15 years and 
older with data available on cardiovascular risk factors. 
Each person in the simulated population was assigned 
systolic and diastolic blood pressure; total and high-
density lipoprotein cholesterol; glycated haemoglobin 
(HbA1c); and history of cardiovascular disease (myocardial 
infarc tion, stroke, or congestive heart failure), type 2 
diabetes, and treatment (with blood pressure 
medications, sta tins, or diabetes medications). We 
defined hyper tension as blood pressure of at least 
140/90 mm Hg (per South African definitions) or being 
on blood pressure treatment;13 dyslipidaemia as total 
cholesterol of at least 6·21 mmol/L, low-density 
lipoprotein cholesterol of at least 4·14 mmol/L, high-
density lipoprotein cholesterol less than 1·03 mmol/L, 
triglycerides of at least 2·25 mmol/L, or being on lipid-
lowering treatment;14 and diabetes as HbA1c of at least 
6·5% (48 mmol/mol) or being on glucose-lowering 
treatment.15 We did Monte Carlo sampling to capture the 
covariations between biomarkers and disease history in 
the survey, following multiple imputation of missing 
data with chained equations and adjustment with survey 
sample weights to construct population-representative 
estimates.16 The Monte Carlo sample was equal to the 
South African population and used the complete census 
survey data, incorporating the SANHANES survey 
sample weights and doing repeated sampling 
(10 000 times) to generate the uncertainty in projecting 
from the stratified survey sample population to the full 
national population. We did prespecified subgroup 
analyses of the SANHANES data to identify variations in 
risk factors and treatment relations among key societal 
divisions in the population. Subgroup analyses were 
done by sex, black African or not black African (which 
includes the four census categories white, coloured, 
Indian or Asian, and other), and poor or not poor (as 
defined by South Africa’s multi dimensional poverty 
index with a composite score cutoff of >0·33 to be 
considered poor11,12).
Third, we did cost-effectiveness analyses comparing 
the WHO PEN and SA PC 101 guidelines.9,10 Following 
current cost-effectiveness analysis guidelines,17 the 
disability-adjusted life-years (DALYs) averted due to 
treatment of hypertension, dyslipidaemia, and type 2 
diabetes and the associated costs of treatment were 
computed for each simulated individual, adopting a 
life-course approach to calculate the DALYs averted and 
costs accumulated over the remainder of the anticipated 
lifetime of each person alive or entering the population 
aged 16 years or older during a simulated 10-year policy 
planning horizon. Following current modelling guide-
lines,18 the policy planning horizon is the period over 
which the population of interest is determined, such that 
a 10-year horizon means that all people aged 16 years or 
older or newly entering that age group over the next 
10 years are simulated; the cohort is then followed over 
their full life-course, meaning that the actual simulation 
period is typically longer than 10 years, subject to the 
individual’s simulated life-course over each stochastic 
iteration subject to the age-specific and sex-specific 
mortality rate.
Simulations were repeated 10 000 times while sampling 
with replacement from the distribution of all input 
parameter values (see appendix) to compute 95% CIs 
around the primary and secondary outcome metrics and 
around the incremental cost-effectiveness ratio (ICER) 
calculations.
Analyses were done in R (version 3.4.3). All parameters 
and equations are detailed in the appendix, with a link to 
the program code for replication.
The study was deemed exempt from human subjects 
review by the Stanford University Institutional Review 
Board (e-Protocol #39274).
Treatment simulations
We simulated three treatment scenarios. First, in the base 
case simulation, existing levels of treatment were 
continued on the basis of the rate of self-reported 
treatment for elevated blood pressure, dyslipidaemia, and 
type 2 diabetes, given measured levels of blood pressure, 
lipids, and HbA1c in SANHANES. Second, in the WHO 
PEN simulation, treatments were added to achieve the 
blood pressure, lipid, and diabetes glucose control 
guidelines depicted in figure 2A. Alternatively, in the 
third and final simulation (SA PC 101), treatments were 
added to achieve the alternative blood pressure, lipid, and 
diabetes glucose control guidelines depicted in figure 2B.
In all three simulations, we compared outcomes at the 
aspirational level of achieving access to treatment among 
70% of the population (allowing variation from 60% to 
80% in sensitivity analyses), with 70% of the population 
with access to treatment subsequently adhering to the 
therapy and receiving DALY benefits and the remaining 
Figure 1: Modelling approach
DALYs=disability-adjusted life-years. RECODe=risk equations for complications of type 2 diabetes. SANHANES=South African National Health and Nutrition 
Examination Survey.
Simulate population 
of South Africa 
(census data)
Population simulation Risk factor estimation Cost-effectiveness analysis
Simulate 
cardiovascular risk 
factors (SANHANES
data)
Estimate baseline
cardiovascular and 
diabetes outcome risk 
(WHO, Harvard, and 
RECODe equations)
Use trial data to
estimate relative risk 
reduction with 
treatment
Extract cost of
treatment for risk 
factors and outcomes 
using South African
cost data and guidelines
Estimate DALYs
averted and costs
associated with
treatment
See Online for appendix
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30% who have access producing costs from receiving 
therapy but not DALY benefits; these estimates are based 
on the best-case scenarios observed in European 
countries19–22 and were applied equally between the two 
guideline simulations for fair comparison.
Outcomes
The primary outcome was total DALYs averted through 
treatment of all cardiovascular disease or microvascular 
type 2 diabetes complications per 1000 population. 
Secondary component outcomes included in the total 
were DALYs averted from each of atherosclerotic 
cardiovascular disease (non-fatal myocardial infarctions 
or coronary heart disease deaths, or fatal or non-fatal 
stroke); congestive heart failure exacerbations; renal 
failure or end-stage renal disease due to hypertensive or 
diabetic nephropathy; severe vision loss attributable to 
diabetic retinopathy; and pressure sensation loss or 
further severe diabetic neuropathy. DALY disutility 
weights for all outcomes were taken from previously 
published primary surveys23 and incorporated into a 
total DALY calculation for each simulated individual 
by calculating their individualised baseline annual risk 
of each outcome, subject to competing risks from 
cardiovascular and non-cardiovascular all-cause mortality 
for their age and sex, and adjusted for the disability 
weight for each condition.24–26 As per each guidelines’ 
recommendation, the baseline risk of myocardial 
infarction and stroke was estimated using the 
WHO and International Society of Hypertension 
equations calibrated to the South African population for 
the WHO PEN guidelines by calibrating the baseline 
hazard rate in the equations to the myocardial infarction 
and stroke rate in the population,27 and using the Harvard 
and National Health and Nutrition Examination Survey 
equations for the SA PC 101 guidelines,28 with twice the 
Figure 2: Alternative guidelines for management of elevated blood pressure, dyslipidaemia, and type 2 diabetes for South African providers
The management flow is shown according to the WHO PEN (A) and SA PC 101 (B) guidelines. ACE=angiotensin-converting enzyme. SA PC 101=South Africa’s Primary Care 101. PEN=package of 
essential non-communicable disease interventions.
Medication
type Blood pressure medication Statins Glycaemic medication
Patient
characteristics
Treatment
Non-diabetic with 
10-year cardiovascular 
disease risk of 20% to 
<30% AND blood pressure 
≥140/90 mm Hg
Non-diabetic with 
10-year cardiovascular 
disease risk of ≥30% or 
history of cardiovascular 
disease, heart failure, or 
kidney disease AND blood 
pressure ≥130/80 mm Hg
<55 years of age: thiazide 
diuretics or ACE inhibitors
≥55 years of age: thiazide 
diuretics or calcium 
channel blockers
Thiazide diuretics or ACE 
inhibitors
Statin (simvastatin 
10 mg daily in South 
Africa)
Metformin, then 
sulfonylurea, then insulin
to target fasting blood 
glucose <7 mmol/L
Non-diabetic with any 
cardiovascular risk AND 
blood pressure  
≥160/100 mm Hg
Diabetic with blood 
pressure ≥130/80 mm Hg
History of cardiovascular 
disease OR diabetic aged 
40 years or older with 
10-year cardiovascular 
disease risk ≥30% OR 
history of cardiovascular 
disease, heart failure, or 
kidney disease OR total 
cholesterol ≥8 mmol/L
Diabetic with fasting 
blood glucose >7 mmol/L
Medication
type Blood pressure medication Statins Glycaemic medication
Patient
characteristics
Treatment
Non-diabetic with 
cardiovascular disease, 
heart failure, or kidney 
disease AND blood 
pressure ≥130/80 mm Hg
Non-diabetic without 
cardiovascular disease, 
heart failure, or kidney 
disease AND blood 
pressure ≥140/90 mm Hg
Thiazide diuretics, then 
ACE inhibitors, then 
calcium channel blockers, 
then β blocker, to blood 
pressure <140/90 mm Hg
Thiazide diuretics, then 
ACE inhibitors, then 
calcium channel blockers, 
then β blocker, to blood 
pressure <130/80 mm Hg
Statin (simvastatin 
10 mg daily in 
South Africa)
 Metformin, then 
sulfonylurea, then insulin
to target HbA1c >7%
(53 mmol/mol) 
Diabetic with blood 
pressure ≥140/80 mm Hg
Diabetic with HbA1c >7% 
(53 mmol/mol) 
A WHO PEN
B SA PC 101
ACE inhibitors, then 
thiazide diuretics, then 
calcium channel 
blockers, then β blocker, 
to blood pressure 
<120–140/70–80 mm Hg
History of cardiovascular 
disease OR 10-year 
cardiovascular disease 
risk >30% OR diabetic 
with hypertension, 
obesity, smoking, or 
older than 40 years 
of age
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baseline risk of recurrence estimated for those with a 
prior history of myocardial infarction or stroke.29 The 
baseline risk of all other outcomes was based on the risk 
equations for complications of type 2 diabetes30,31 
calibrated to the South African population, for the 
portion of the population without previous self-reported 
history of the pertinent outcome; the baseline hazard rate 
was calibrated for each outcome to match the Global 
Burden of Disease incidence estimates.32 No cardio-
vascular risk equations have been developed using longi-
tudinal data from South Africa, so we deferred to the risk 
equations specified in each guideline to estimate that 
guideline’s impact, for unbiased comparison.
Relative risk reductions through treatment
To estimate the DALYs averted by treatment, the baseline 
DALYs associated with each individual for each condition 
were adjusted by the relative risk reduction attributable to 
each treatment (see detailed tables and equations in the 
appendix). For blood pressure treatment, the relative risk 
reductions for myocardial infarctions and strokes were 
estimated using the Smith-Spangler equation calculating 
relative risk as a function of age and change in systolic 
blood pressure;33 the equations had been previously 
validated against data from a meta-analysis29 of 
61 randomised trials. Anticipated change in systolic blood 
pressure was estimated from the mean reduction in 
systolic blood pressure estimated for each medication in a 
prospective meta-analysis34 of 354 randomised trials, given 
the typical drug choice and dosing recommended by 
each guideline (figure 2). The relative risk reduction 
from blood pressure therapy (specifically angiotensin-
converting enzyme inhibitors) for congestive heart failure 
exacerbations was estimated from the SOLVD trial35 
whereas for renal failure, we used a prior systematic 
review36 estimating relative risk reduction by systolic blood 
pressure reduction. For dyslipidaemia treatment, the 
relative risk reduction for myocardial infarction and stroke 
from statin treatment (given the South African guideline’s 
recommendation of simvastatin 10 mg daily) was obtained 
from a meta-analysis37 of 27 randomised trials. Finally, for 
glycaemic treatment of type 2 diabetes, the relative risk 
reductions for each of the nephropathy, neuropathy, and 
retinopathy outcomes from glucose control were taken 
from a prior systematic review and meta-analysis36 of 
randomised trials estimating relative risk reduction by 
HbA1c achieved, where the estimated HbA1c reduction 
typically produced by each therapy in the guidelines was 
taken from an evidence-based review38 incorporating the 
dosing guidelines detailed in the appendix.
Cost-effectiveness analysis 
Concordant with recent updates to cost-effectiveness 
analysis guidelines,18 we analysed cost-effectiveness over 
the life-courses of individuals in the simulated 
population. DALYs and costs were calculated from a 
health-care sector perspective in the absence of reliable 
and consistent data on time costs, unpaid caregiver costs, 
transportation costs, labour market earnings lost, and 
social service costs for a societal perspective. An impact 
inventory specifying each set of costs and their sources is 
specified in the appendix, along with the CHEERS guide-
line checklist for cost-effectiveness analysis reporting.39 
In short, to calculate costs, we extracted information on 
the costs of care for each risk factor and outcome from 
the 2012 South Africa Department of Health Uniform 
Patient Fee Schedule for externally funded patients 
because these most closely align with the costs to the 
health-care services of providing care. For the costs of 
blood tests, 2012 data were not available, so we used 
fees from the South Africa National Health Laboratory 
Services for 2013. Where there were two or more cost 
options for the treatment components of a given risk 
factor or outcome, we chose the most conservative one. 
All costs were updated for inflation to 2018 US$ for 
global comparison, and both costs and DALYs were 
discounted at a standard 3% annual rate. Two ICERs 
were computed: the ICER of expanding from existing 
levels of treatment reflected in SANHANES to the WHO 
PEN guidelines and the ICER of expanding from existing 
levels of treatment reflected in SANHANES to the 
SA PC 101 guidelines.
Role of the funding source
The funders had no role in the design, conduct, analysis, 
or writing up of the study. The corresponding author had 
full access to the data and took the decision to submit for 
publication.
Results
The SANHANES input data revealed high levels of 
hypertension, dyslipidaemia, and type 2 diabetes among 
the South African population aged 15 years or older, yet 
most of the population reported being untreated for 
these conditions (table 1). Based on the SANHANES 
study sample weights, 24·8% of the South African 
population aged 15 years and older would have 
hypertension, 17·5% would have dyslipidaemia, and 
15·3% would have diabetes.
The SANHANES data revealed that for blood pressure 
treatment, treatment was particularly low among men. 
For lipid treatment, treatment rates were particularly low 
among black Africans (table 1). SANHANES self-
reported treatment survey questions suggested that 
1257 (71·4%) of the 1761 people with hypertension 
received treatment, of whom 888 (70·6%) achieved 
blood pressure no higher than 140/90 mm Hg (table 1). 
By contrast, only 106 (3·5%) of the 3042 people with 
dyslipidaemia received statin treatment, among whom 
12 (11·3%) achieved low-density lipo protein no higher 
than 2·5 mmol/L. However, 436 (58·4%) of the 
747 people with diabetes received glucose-lowering 
treatment, among whom 39 (8·9%) achieved HbA1c no 
higher than 7% (53 mmol/mol; table 1).
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In the base case simulation in which the existing 
levels of treatment were continued, our micro-
simulation—accounting for competing mortality risks 
over the life-course—suggested that the simulated 
population would experience a burden of 40·0 DALYs 
(95% CI 29·5–52·0) from cardiovascular disease or 
Male Female
Black African Not black African Black African Not black African
Poor (n=3654) Not poor 
(n=1276)
Poor (n=1222) Not poor 
(n=1521)
Poor (n=5055) Not poor 
(n=1638)
Poor (n=1505) Not poor 
(n=1872)
Demographics
Age, years (n=17 633) 35·2 
(16·0–69·0)
35·9 
(16·0–66·0)
39·8 
(16·0–68·0)
40·0 
(16·0–69·0)
38·7 
(16·0–74·0)
38·9 
(17·0–72·0)
40·8 
(17·0–72·0)
41·4 
(17·0–70·0)
Blood pressure
Systolic, mm Hg (n=7048) 130·7 
(102·0–173·0)
130·6 
(103·0–172·0)
133·3 
(101·0–171·0)
133·8 
(105·0–175·0)
128·5 
(100·0–175·0)
128·9 
(99·0–174·0)
130·0 
(101·0–171·5)
131·1 
(101·0–176·0)
Diastolic, mm Hg (n=7039) 72·9 
(53·0–98·0)
72·7 
(52·0–94·0)
75·6 
(54·0–99·0)
74·9 
(54·0–96·0)
74·5 
(55·0–98·0)
75·5 
(55·0–99·0)
75·5 
(57·0–97·0)
75·4 
(55·0–98·0)
Hypertension (n=7099)* 236/1341 (18%) 66/357 (18%) 97/394 (25%) 100/407 (25%) 636/2551 (25%) 202/649 (31%) 198/662 (30%) 226/738 (31%)
Undergoing blood pressure 
treatment (n=1761)
128/236 (54%) 46/66 (70%) 58/97 (60%) 64/100 (64%) 464/636 (73%) 161/202 (78%) 151/198 (76%) 185/226 (82%)
Blood pressure 
≤140/90 mm Hg with 
treatment (n=1257)
81/128 (63%) 36/46 (78%) 42/58 (72%) 52/64 (81%) 316/464 (68%) 111/161 (69%) 116/151 (77%) 134/185 (72%)
Lipids
Total cholesterol, mmol/L 
(n=5419)
4·1 (2·7–5·8) 4·1 (2·7–5·8) 4·5 (2·9–6·4) 4·7 (3·1–6·8) 4·4 (2·8–6·4) 4·5 (3·0–6·5) 4·8 (3·1–7·0) 5·0 (3·2–7·3)
High-density lipoprotein 
cholesterol, mmol/L (n=5394)
1·2 (0·7–2·0) 1·2 (0·7–2·0) 1·3 (0·8–2·2) 1·2 (0·7–2·0) 1·3 (0·7–2·0) 1·3 (0·8–2·1) 1·3 (0·8–2·2) 1·3 (0·8–2·0)
Low-density lipoprotein 
cholesterol, mmol/L (n=3308)
2·2 (1·2–3·7) 2·3 (1·2–3·7) 2·4 (1·1–4·4) 2·7 (1·3–4·4) 2·6 (1·3–4·2) 2·7 (1·2–4·6) 2·9 (1·4–4·6) 3·0 (1·4–5·1)
Triglycerides (fasting), mmol/L 
(n=534)
1·4 (0·5–2·7) 1·6 (0·5–5·0) 1·1 (0·5–1·9) 2·1 (0·6–9·3) 1·2 (0·4–2·9) 1·0 (0·4–2·2) 1·1 (0·6–1·9) 1·2 (0·5–2·7)
Dyslipidaemia (n=17 743)† 514/3654 (14%) 141/1276 (11%) 243/1222 (20%) 243/1521 (16%) 911/5055 (18%) 258/1638 (16%) 379/1505 (25%) 453/1872 (24%)
Undergoing lipid-lowering 
treatment (n=3042)
0 3/141 (2%) 16/243 (7%) 22/243 (9%) 6/911 (1%) 6/258 (2%) 17/379 (4%) 36/453 (8%)
Achieving low-density 
lipoprotein ≤2·5 mmol/L with 
treatment (n=106)
·· 0 3/16 (19%) 2/22 (9%) 0 0 5/17 (29%) 2/36 (6%)
Diabetes
HbA1c [mmol/mol] (n=4710) 5·8% (4·9–6·5) 
[40 (30–48)]
5·9% (5·0–7·4) 
[41 (31–57)]
5·9% (5·0–6·8) 
[41 (31–51)]
6·1% (5·1–8·7) 
[43 (32–72)]
5·9% (4·9–7·1) 
[41 (30–54)]
5·1% (5·0–9·1) 
[32 (31–76)]
6·0% (5·0–8·8) 
[42 (31–73)]
6·1% (5·1–8·6) 
[42 (32–70)]
Diabetes (n=4877)‡ 81/873 (9%) 36/255 (14%) 38/317 (12%) 64/312 (21%) 227/1603 (14%) 87/443 (20%) 90/511 (18%) 124/563 (22%)
Undergoing glucose-lowering 
treatment (n=747)
47/81 (58%) 23/36 (64%) 26/38 (68%) 40/64 (63%) 119/227 (52%) 49/87 (56%) 57/90 (63%) 75/124 (60%)
Achieving HbA1c ≤7% 
(53 mmol/mol) with 
treatment (n=436)
6/47 (13%) 1/23 (4%) 4/26 (15%) 3/40 (8%) 10/119 (8%) 5/49 (10%) 4/57 (7%) 6/75 (8%)
Prior cardiovascular history (self-reported)
Myocardial infarction 
(n=15 267)
110/3079 (4%) 25/1072 (2%) 45/1008 (4%) 41/1198 (3%) 261/4522 (6%) 73/1483 (5%) 47/1298 (4%)  58/1607 (4%)
Congestive heart failure 
(n=15 232)
39/3067 (1%) 13/1064 (1%) 12/1010 (1%) 11/1197 (1%) 120/4512 (3%) 26/1476 (2%) 22/1299 (2%) 28/1607 (2%)
Stroke (n=15 282) 57/3088 (2%) 15/1067 (1%) 30/1007 (3%) 36/1199 (3%) 105/4533 (2%) 29/1474 (2%) 25/1305 (2%) 47/1609 (3%)
Data are n/N (%) or mean (95% CI). Studied population comprised 17 743 individuals aged 15 and older with data available on cardiovascular risk factors. Results incorporate survey sample weights to adjust for 
sample selection and provide nationally representative estimates. Poverty was defined by the South African multidimensional poverty index, which defines poor versus non-poor status based on health and 
nutrition assets, educational attainment, and material assets. HbA1c=glycated haemoglobin. SANHANES=South African National Health and Nutrition Examination Survey. *Hypertension was defined as blood 
pressure ≥140/90 mm Hg or taking blood pressure-lowering medications. †Dyslipidemia was defined as measured total cholesterol ≥6·21 mmol/L, low-density lipoprotein cholesterol ≥4·14 mmol/L, 
high-density lipoprotein cholesterol <1·03 mmol/L, fasting triglycerides ≥2·25 mmol/L, or taking lipid-lowering medications. ‡Diabetes was defined as measured haemoglobin A1c ≥6·5% (48 mmol/mol) or 
taking glucose-lowering medications.
Table 1: Characteristics of the studied SANHANES population
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type 2 diabetes micro vascular complications per 
1000 population per year (table 2).40 Of these DALYs, 
16·8 (42%) were from years of life lost (based on 
WHO life expectancy estimates41) and the remaining 
23·2 (58%) were from years of life lived with disability. 
The total 40·0 DALYs per 1000 population per year were 
also 74% attributable to cardiovascular disease versus 
23% attributable to type 2 diabetes microvascular 
complications. The base case simulation suggested that 
most estimated DALYs were attributable to athero-
sclerotic cardiovascular disease, followed by congestive 
heart failure, renal failure or end-stage renal disease, 
diabetic retinopathy, and diabetic neuropathy (table 2).
In the base case simulation, the overall premature 
mortality rate (defined as mortality for those younger 
than 70 years of age) due to cardiovascular disease was 
39·5 deaths (95% CI 28·0–52·0) per 1000 population per 
year. The populations facing the highest DALY burden 
from cardiovascular disease and type 2 diabetes 
complications were men (25·7 [64%] of total DALYs vs 
14·3 [36%] among women), black Africans (23·0 [58%] of 
total DALYs vs 17·0 [43%] among non-black Africans), 
and the poor (24·1 [60%] of total DALYs vs 15·9 [40%] 
among non-poor populations).
The base case cost analysis suggested an average cost 
of US$607 820 (95% CI 513 818–705 805) per 1000 popu-
lation per year for cardiovascular and type 2 diabetes 
complications, most of which was attributable to medical 
treatment for atherosclerotic cardiovascular disease, 
followed by type 2 diabetes and end-stage renal disease 
(table 2).
WHO PEN guideline implementation would be expected 
to produce a 4·2 percentage point rise in the proportion of 
the population prescribed blood pressure medications, a 
16·0 percentage point rise in the proportion prescribed 
statins, and a 1·2 percentage point rise in the proportion 
prescribed glucose-lowering medications. A small portion 
of people would be removed from medication because they 
would not be indicated to have treatment under the WHO 
PEN guidelines despite currently being on treatment 
(7% of those currently on blood pressure medications, 
1% of those currently on statins, and 1% of those currently 
on glucose-lowering medications). Rather than simply 
prescribing a higher number of medications, the WHO 
PEN implementation also increased the targeting of 
medications towards those at highest risk for cardiovascular 
disease and type 2 diabetes complications. Specifically, the 
average risk over 10 years of atherosclerotic cardiovascular 
disease for those prescribed blood pressure or statin 
medications was 25·9% in the base case simulation 
compared with 31·1% in the WHO PEN simulation; 
similarly, the average risk over 10 years for any 
microvascular complication of diabetes for those 
prescribed glucose-lowering medications was 24·4% in the 
base case simulation compared with 26·7% in the WHO 
PEN simulation.
Base case (current levels of 
treatment)
WHO PEN guidelines 
implemented
SA PC 101 guidelines implemented
DALYs per 1000 population per year
All simulated outcomes 40·0 (29·5 to 52·0) 32·9 (24·4 to 44·7) 32·5 (24·4 to 44·8)
Atherosclerotic cardiovascular disease 18·7 (15·8 to 21·8) 13·7 (11·7 to 16·3) 13·4 (11·7 to 16·2)
Congestive heart failure 10·7 (7·3 to 14·6) 9·9 (6·6 to 13·9) 9·8 (6·6 to 13·9)
Renal failure or end-stage renal disease 9·2 (5·5 to 13·5) 8·2 (5·2 to 12·8) 8·2 (5·2 to 13·0)
Diabetic retinopathy 0·8 (0·5 to 1·3) 0·6 (0·5 to 1·0) 0·6 (0·5 to 1·0)
Diabetic neuropathy 0·6 (0·4 to 0·8) 0·5 (0·4 to 0·7) 0·5 (0·4 to 0·7)
Health-care costs per 1000 population per year (2018 US$) 
All simulated risk factors and outcomes 607 820 (513 818 to 705 805) 482 950 (296 612 to 692 370) 421 055 (194 667 to 600 208)
Hypertension 26 429 (26 326 to 26 533) 27 019 (23 761 to 29 750) 39 165 (35 564 to 42 830)
Dyslipidaemia 6585 (6308 to 6860) 10 347 (9575 to 10 484) 10 506 (9743 to 11 237)
Type 2 diabetes 183 006 (170 185 to 195 023) 139 011 (84 559 to 192 761) 77 502 (52 783 to 95 728)
Atherosclerotic cardiovascular disease 248 108 (226 170 to 270 567) 189 288 (153 101 to 225 400) 187 799 (151 400 to 235 606)
Congestive heart failure 29 243 (21 778 to 37 251) 24 533 (11 958 to 40 659) 24 451 (11 958 to 40 659)
Renal failure or end-stage renal disease 138 195 (87 520 to 192 544) 117 461 (36 524 to 219 146) 118 475 (30 437 to 213 058)
Diabetic retinopathy 587 (371 to 808) 426 (91 to 820) 438 (68 to 820)
Diabetic neuropathy 2096 (1486 to 2752) 1884 (804 to 3100) 1884 (804 to 3100)
Incremental cost-effectiveness ratio* ·· −17 587 (−42 589 to −1840) −24 902 (−62 579 to −14 666)
Table shows current treatment levels (base case) compared with the scale-up from currently observed levels of treatment to 70% population access per the WHO PEN or 
SA PC 101 guidelines. 95% CIs in brackets are calculated by re-running the model 10 000 times while repeatedly Monte Carlo sampling with replacement from the 
distributions of all input parameters to estimate uncertainty in the outcome metrics. Costs are given in US$. DALYs=disability-adjusted life-years. PEN=package of essential 
non-communicable disease interventions. SA PC 101=South Africa’s Primary Care 101. *Change in cost divided by change in DALYs, compared with the base case.
Table 2: DALYs, costs, and incremental cost-effectiveness of treating elevated blood pressure, dyslipidemia, and type 2 diabetes for the South African 
population
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When WHO PEN guidelines were implemented, 
South Africans in our simulated population experienced a 
burden of 32·9 DALYs (95% CI 24·4–44·7) per 
1000 population per year from cardiovascular disease or 
type 2 diabetes complications, a decrease of 7·1 DALYs 
from the base case simulation of current treatment levels 
(table 2). The largest improvements in DALYs due to 
cardiovascular disease and type 2 diabetes complications 
gained from implementing WHO PEN were from 
atherosclerotic cardiovascular disease (5·0 DALYs averted 
per 1000 population per year), followed by renal failure or 
end-stage renal disease (1·0 DALYs averted), then 
congestive heart failure (0·8 DALYs averted), diabetic 
retinopathy (0·2 DALYs averted), and finally diabetic 
neuropathy (0·1 DALYs averted; table 2). Our results 
suggested that male, black African, and poor populations 
benefited most, although all population estimates had 
wide CIs (figure 3). The overall premature mortality rate 
due to cardiovascular disease was 23·4 deaths (95% CI 
14·0–34·0) per 1000 population per year, a 40·8% reduction 
from the base case.
Implementation of the WHO PEN guidelines increased 
costs from treatment of hypertension and dyslipidaemia, 
while saving costs through averted atherosclerotic 
cardiovascular disease events, congestive heart failure 
exacerbations, and microvascular compli cations of 
diabetes (table 2). The net cost estimates for the WHO 
PEN simulation were negative due to averted cardio-
vascular and microvascular events, saving on average 
$124 870 (95% CI 13 435–217 206) per 1000 population per 
year compared with the base case. The incremental cost-
effectiveness of implementing WHO PEN rather 
than the current treatment would be a saving of $17 587 
(1840–42 589) per DALY averted. The total absolute cost, 
however, would be $482 950 (296 612–692 370) per 
1000 population per year, as compared with the current 
South African health-care budget for primary health-care 
services of $374 per 1000 population per year (excluding 
services for tuberculosis and HIV).42
SA PC 101 guideline implementation produced a 
12·6 percentage point rise in the proportion of the 
population prescribed blood pressure medications, a 
14·9 percentage point rise in the proportion prescribed 
statins, and a 0·6 percentage point rise in the proportion 
prescribed glucose-lowering medications. 7% of those 
currently on blood pressure medications, 1% of those 
cur rently on statins, and 1% of those currently on 
glucose-lowering medications would be removed from 
medication because they would not be indicated to have 
treatment under the SA PC 101 guidelines, nearly fully 
overlapping with those removed by WHO PEN.
When SA PC 101 guidelines were implemented, 
South Africans in our simulated population experienced 
a burden of 32·5 DALYs (95% CI 24·4–44·8) from 
cardio vascular disease or type 2 diabetes complications 
per 1000 population per year, fewer than both in the base 
case and WHO PEN simulations (table 2). The slightly 
higher number of DALYs averted under SA PC 101 than 
under the WHO PEN guidelines was due to a greater 
proportion of the population being prescribed blood 
pressure medication and the associated reductions in 
atherosclerotic cardiovascular disease; a larger number 
of people with slightly lower average risk were treated 
under SA PC 101 compared with the smaller number of 
people with higher average risk treated under WHO 
PEN. In the SA PC 101 simulation, the average risk over 
10 years of atherosclerotic cardiovascular disease for 
those prescribed blood pressure or statin medications 
was 23·1% and the average risk for any microvascular 
complication of diabetes for those prescribed glucose-
lowering medications was 27·8%. Compared with the 
base case simulation, the greatest reductions in DALYs 
were from athero sclerotic cardio vascular disease 
(5·3 DALYs averted per 1000 population per year), 
followed by renal failure or end-stage renal disease 
(1·0 DALYs averted), then congestive heart failure 
(0·9 DALYs averted), diabetic retinopathy (0·2 DALYs 
averted), and finally diabetic neuropathy (0·1 DALYs 
averted; table 2). The male population benefited more 
than the female population but no disproportionate 
benefits were observed between black Africans and non-
black Africans or between poor and non-poor populations 
(figure 3). The overall pre mature mortality rate due to 
cardiovascular disease was 22·1 deaths (95% CI 
13·0–32·0) per 1000 population per year, a 44·1% 
reduction from the base case and a 5·6% reduction from 
the WHO PEN simulation.
Compared with the WHO PEN guidelines, implemen-
tation of the SA PC 101 guidelines would be expected to 
Figure 3: DALYs averted from treatment according to different guidelines of elevated blood pressure, 
dyslipidaemia, and type 2 diabetes for the South African population, by sex, race and ethnicity, and 
socioeconomic status
The figure shows DALYs averted by treatment according to the WHO PEN and SA PC 101 guidelines. 
DALY=disability-adjusted life-year. PEN=package of essential non-communicable disease interventions. 
SA PC 101=South Africa’s Primary Care 101.
DALYs avertedWHO PEN
Sex
Female
Male
Race
Black
Non-black
Poverty
Poor
Not poor
 2·39 (2·02–2·76)
 4·71 (3·98–5·44)
 3·97 (3·35–4·58)
 3·13 (2·65–3·62)
 3·73 (3·16–4·31)
 3·37 (2·84–3·89)
SA PC 101
Sex
Female
Male
Race
Black
Non-black
Poverty
Poor
Not poor
 2·54 (2·08–3·00)
 4·96 (4·07–5·85)
 3·81 (3·12–4·50)
 3·69 (3·03–4·35)
 3·70 (3·03–4·36)
 3·80 (3·12–4·49)
421 5 63
DALYs averted per 1000 population per year (95% CI)
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increase costs for treatment of blood pressure. They would 
require similar costs for dyslipidaemia—the costs would 
be slightly higher than under the WHO PEN guidelines 
due to a younger group being treated and thus a longer 
time of paying for statins over the life-course—and would 
reduce costs for glycaemic treatment for type 2 diabetes 
(table 2). Most medical costs from complications through 
the SA PC 101 implementation were averted from 
atherosclerotic cardiovascular disease events but com-
pared with the WHO PEN implementation, fewer costs 
were averted from microvascular complications of 
diabetes (table 2). Overall, the SA PC 101 implementation 
was more cost saving than the WHO PEN guideline, 
saving on average $186 765 (95% CI 105 597–319 151) per 
1000 population per year compared with the base case. 
The total absolute cost, however, of SA PC 101 would 
be only marginally lower than under WHO PEN at 
$421 055 (194 667–600 208) per 1000 population per year. 
The incremental cost-effectiveness of implementing 
SA PC 101 over the current treatment would be a saving of 
$24 902 (14 666–62 579) per DALY averted.42
In sensitivity analyses, ICERs were not substantially 
changed under either guideline if access to treatment 
changed from the base case of 70% of the population 
to 60% or 80% (appendix). The incremental cost-
effectiveness of blood pressure and lipid therapies 
became more pronounced at lower levels of baseline 
treatment because the incremental impact of treatment 
was more potent with lower baseline coverage levels. 
We found that at least 46·7% of the population 
with hypertension and hyperlipidaemia would need to be 
diagnosed and treated for these conditions to achieve 
the 30% premature mortality reduction Sustainable 
Development Goal, which would not require new blood 
pressure or lipid screening but would require more 
treatment initiation and adherence.
Discussion
We found high rates of cardiovascular and microvascular 
risk factors across demographic groups, with low 
treatment levels (particularly for lipid treatment) among 
male, black African, and poor populations in South 
Africa. Although treatment subsidisation is high among 
the poor in South Africa, various barriers to access to 
care—including cultural, trust, and financial barriers to 
getting to care—conspire with a higher level of risk 
factors in poor people to result in a disproportionate 
burden. Given the distribution of risk factors and 
treatments at present, our microsimulation suggested a 
high burden of DALYs from atherosclerotic cardiovascular 
disease, followed by congestive heart failure and diabetes 
microvascular complications. With implementation of 
the WHO PEN guidelines, we would anticipate a 
considerably higher proportion of the population treated 
with statins, followed by increased treatment for 
hypertension and then glycaemic control for diabetes. But 
we additionally found that implementation of the 
SA PC 101 guidelines averted slightly more overall DALYs 
and had better cost-effectiveness than did implementation 
of the WHO PEN guidelines. The key benefits of the 
SA PC 101 guidelines in terms of DALYs was a result of 
more assertive blood pressure treatment, particularly for 
high-risk patients, whereas the benefits, in terms of costs, 
were primarily from less assertive blood glucose control 
than under the WHO PEN guidelines. We found that if 
either guidelines were implemented with coverage rates 
similar to a well performing European health system, the 
Sustainable Development Goals target 3.4 (reduction in 
premature mortality from non-communicable diseases of 
one third) would be readily achieved.
Our findings address considerable debate in the 
literature regarding whether or not cardiovascular diseases 
and their risk factors affect a sufficient proportion of the 
population, particularly lower-income groups, to justify 
widespread treatment.43,44 Our microsimulation modelling 
approach has a key advantage over traditional Markov 
models of simulating entire distributions of risk, rather 
than just an average risk level, thus capturing hetero-
geneities in risk and benefit of treatment. Our results are 
notable for uniquely assessing inequalities in the disease 
burden and benefit from using nationally representative 
data, which suggest that par ticularly disadvantaged popu-
lations might disproportionately benefit from assertive 
treatment. Additionally, we address questions about risk 
factor prioritisation. Our results suggest that treatment 
with blood pressure agents and statins might need greater 
prioritisation at the population level for people at high 
cardiovascular risk than blood glucose medications, while 
recognising the importance of the latter at the individual 
level. This contrasts with observed treatment levels despite 
a lower monthly cost of blood pressure or statin treatment 
than of sulfonylurea or insulin treatment in South Africa, 
as is the case in many other middle-income countries.45 
Our findings on prioritisation are relevant to many 
countries imple menting WHO PEN or SA PC 101 
guidelines; notably, the South African PC 101 guidelines 
are now being implemented in Botswana, Nigeria, and 
Brazil.46 The SA PC 101 guidelines have an explicit focus 
on population equity.
There are important limitations to our analysis. 
Simulation studies cannot predict the future and can 
only anticipate potential outcomes under the premise 
that the effectiveness observed in randomised trials and 
meta-analyses will be realised in practice. Achieving 
European levels of treatment access will undoubtedly 
require access and adherence initiatives that would 
increase costs and make the cost-effectiveness of this 
approach less attractive. Improving access to care goes 
beyond improving availability of treatment and requires 
overcoming barriers including culture, trust, and the 
financial implications of getting to care. These issues are 
particularly relevant in South Africa given its apartheid 
past. Lack of reliable data on costs of successful access 
and adherence initiatives in South Africa mean that we 
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have not included these in our analysis. However, the 
costs that we have used do include the costs of 
infrastructure and personnel to deliver treatment and 
are not limited to the costs of medications or equipment. 
Additionally, improving availability of treatment and 
hence results of accessing health care can engender 
trust in and usage of those services.47 An additional 
consideration is that randomised trials and meta-
analyses that focus on estimating results among mostly 
North American and European populations might not 
accurately reflect the effectiveness of therapy among 
diverse South African populations. We have also 
calculated cost-effectiveness using broad international 
guidelines that focus on value per dollar spent; however, 
ministries of finance have numerous competing 
priorities when allocating resources, even among highly 
cost-effective interventions, that must be considered on 
the basis of often fluctuating budgets, as well as the 
training needs and physical infrastructure of health-care 
providers and delivery organisations. The SANHANES 
data on which our simulations rely have important gaps, 
particularly the absence of detail concerning access to 
and pricing of tobacco cessation treatments, and 
incomplete coverage of all risk factors across the entire 
sample. However, the data do provide important 
estimates of how the distributions of other major 
cardiovascular disease risk factors are prevalent among 
minority and poor populations, contrary to claims that 
cardiovascular risk would be isolated to higher-income 
groups. The data are nevertheless self-reported for key 
treatment questions, which might lead to overestimation 
of treatment levels due to social acceptability bias (eg, 
not admitting non-adherence) or underestimation of 
treatment if individuals are confused about what 
medications they are taking and what those medications 
are for.
Future research efforts should address the question of 
what key implementation barriers have prevented more 
assertive statin treatment in the South African population. 
Additionally, research efforts should identify how to 
better reach male, black, and poor populations who 
appear to be disproportionately undertreated for their 
chronic disease risk—including analysis of the barriers to 
treatment, such as cultural, social, and economic contexts 
faced by those underserved populations.
As such research is initiated, our results suggest that 
the departments of health of South Africa and similar 
nations prepare assertively for increased burdens of non-
com municable diseases. Our results suggest that the 
SA PC 101 guidelines might be more effective in terms of 
DALYs averted and net overall costs saved than the current 
WHO guidelines for management of blood pressure, 
lipids, and diabetes. Particularly assertive treatment 
across people with hypertension and hyperlipidaemia 
with blood pressure and statin medications might help to 
mitigate a high burden of disease, including among 
historically disadvantaged populations.
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